512 related articles for article (PubMed ID: 24658078)
21. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers.
Attie KM; Allison MJ; McClure T; Boyd IE; Wilson DM; Pearsall AE; Sherman ML
Am J Hematol; 2014 Jul; 89(7):766-70. PubMed ID: 24715706
[TBL] [Abstract][Full Text] [Related]
22. Lyn kinase plays important roles in erythroid expansion, maturation and erythropoietin receptor signalling by regulating inhibitory signalling pathways that control survival.
Slavova-Azmanova NS; Kucera N; Louw A; Satiaputra J; Handoko A; Singer P; Stone L; McCarthy DJ; Klinken SP; Hibbs ML; Ingley E
Biochem J; 2014 May; 459(3):455-66. PubMed ID: 24552351
[TBL] [Abstract][Full Text] [Related]
23. In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes.
Merchav S; Nielsen OJ; Rosenbaum H; Sharon R; Brenner B; Tatarsky I; Scigalla P; Wieczorek L
Leukemia; 1990 Nov; 4(11):771-4. PubMed ID: 2232891
[TBL] [Abstract][Full Text] [Related]
24. Guinea pig serum erythropoietin (EPO) selectively stimulates guinea pig erythroid progenitors: human or mouse erythroid progenitors do not form erythroid burst-forming unit colonies in response to guinea pig serum EPO.
Stopka T; Zivny JH; Goldwasser E; Prchal JF; Necas E; Prchal JT
Exp Hematol; 1998 Aug; 26(9):910-4. PubMed ID: 9694513
[TBL] [Abstract][Full Text] [Related]
25. Erythropoietin stimulates spleen BMP4-dependent stress erythropoiesis and partially corrects anemia in a mouse model of generalized inflammation.
Millot S; Andrieu V; Letteron P; Lyoumi S; Hurtado-Nedelec M; Karim Z; Thibaudeau O; Bennada S; Charrier JL; Lasocki S; Beaumont C
Blood; 2010 Dec; 116(26):6072-81. PubMed ID: 20844235
[TBL] [Abstract][Full Text] [Related]
26. Neutralization of autocrine transforming growth factor-beta in human cord blood CD34(+)CD38(-)Lin(-) cells promotes stem-cell-factor-mediated erythropoietin-independent early erythroid progenitor development and reduces terminal differentiation.
Akel S; Petrow-Sadowski C; Laughlin MJ; Ruscetti FW
Stem Cells; 2003; 21(5):557-67. PubMed ID: 12968110
[TBL] [Abstract][Full Text] [Related]
27. Cellular mechanism of resistance to erythropoietin.
Casadevall N
Nephrol Dial Transplant; 1995; 10 Suppl 6():27-30. PubMed ID: 8524490
[TBL] [Abstract][Full Text] [Related]
28. The erythropoietic effects of interleukin 6 and erythropoietin in vivo.
Ulich TR; del Castillo J; Yin SM; Egrie JC
Exp Hematol; 1991 Jan; 19(1):29-34. PubMed ID: 1989892
[TBL] [Abstract][Full Text] [Related]
29. In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels.
Zwierzina H; Bammer T; Rollinger-Holzinger I; Herold M; Fenaux P; Nüssler V; Hoflehner E; Geissler D
Clin Cancer Res; 1996 Jun; 2(6):1031-8. PubMed ID: 9816264
[TBL] [Abstract][Full Text] [Related]
30. Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and β-Thalassemia.
Parisi S; Finelli C; Fazio A; De Stefano A; Mongiorgi S; Ratti S; Cappellini A; Billi AM; Cocco L; Follo MY; Manzoli L
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467674
[TBL] [Abstract][Full Text] [Related]
31. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis.
Fenaux P; Kiladjian JJ; Platzbecker U
Blood; 2019 Feb; 133(8):790-794. PubMed ID: 30602619
[TBL] [Abstract][Full Text] [Related]
32. In vivo suppression of erythropoiesis by tumor necrosis factor-alpha (TNF-alpha): reversal with exogenous erythropoietin (EPO).
Johnson CS; Cook CA; Furmanski P
Exp Hematol; 1990 Feb; 18(2):109-13. PubMed ID: 2303102
[TBL] [Abstract][Full Text] [Related]
33. The RAR-RXR as well as the RXR-RXR pathway is involved in signaling growth inhibition of human CD34+ erythroid progenitor cells.
Rusten LS; Dybedal I; Blomhoff HK; Blomhoff R; Smeland EB; Jacobsen SE
Blood; 1996 Mar; 87(5):1728-36. PubMed ID: 8634418
[TBL] [Abstract][Full Text] [Related]
34. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.
Rainville N; Jachimowicz E; Wojchowski DM
Expert Opin Ther Targets; 2016; 20(3):287-301. PubMed ID: 26419263
[TBL] [Abstract][Full Text] [Related]
35. Effect of Tumor Necrosis Factor-Alpha on Erythropoietin and Erythropoietin Receptor-Induced Erythroid Progenitor Cell Proliferation in β-Thalassemia/Hemoglobin E Patients.
Tanyong DI; Panichob P; Kheansaard W; Fucharoen S
Turk J Haematol; 2015 Dec; 32(4):304-10. PubMed ID: 26376749
[TBL] [Abstract][Full Text] [Related]
36. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors.
Mies A; Platzbecker U
Semin Hematol; 2017 Jul; 54(3):141-146. PubMed ID: 28958287
[TBL] [Abstract][Full Text] [Related]
37. Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts.
Mies A; Hermine O; Platzbecker U
Curr Hematol Malig Rep; 2016 Dec; 11(6):416-424. PubMed ID: 27595736
[TBL] [Abstract][Full Text] [Related]
38. Activin type IIA and IIB receptors mediate Gdf11 signaling in axial vertebral patterning.
Oh SP; Yeo CY; Lee Y; Schrewe H; Whitman M; Li E
Genes Dev; 2002 Nov; 16(21):2749-54. PubMed ID: 12414726
[TBL] [Abstract][Full Text] [Related]
39. An optimized system for studies of EPO-dependent murine pro-erythroblast development.
Zhang D; Johnson MM; Miller CP; Pircher TJ; Geiger JN; Wojchowski DM
Exp Hematol; 2001 Nov; 29(11):1278-88. PubMed ID: 11698123
[TBL] [Abstract][Full Text] [Related]
40. Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction.
Fontenay-Roupie M; Bouscary D; Guesnu M; Picard F; Melle J; Lacombe C; Gisselbrecht S; Mayeux P; Dreyfus F
Br J Haematol; 1999 Aug; 106(2):464-73. PubMed ID: 10460607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
